Opendata, web and dolomites

FRAME SIGNED

FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FRAME project word cloud

Explore the words cloud of the FRAME project. It provides you a very rough idea of what is the project "FRAME" about.

healthy    entire    personalized    individualized    patient    dna    frames    breast    start    proqr    point    founder    alone    track    usually    activation    combine    first    develops    team    body    shown    solution    group    breaking    entrepreneurs    tumor    effect    benefit    time    foreign    mutations    uterine    50    quo    weeks    status    types    ceo    checkpoint    shelf    critical    care    ambition    therapeutics    dutch    vaccines    reducing    company    strategies    read    shift    inhibitors    balanced    manufacturing    melanoma    lung    requiring    treatment    neoantigens    discovered    biotech    consists    colon    source    shared    licensed    cancers    ratio    therapeutic    off    vaccination    strategy    ground    alter    successful    clinical    imprcost    record    months    kidney    anti    vaccine    patients    health    economics    days    activate    crucell    entirely    frameshift    frame    sequences    expressed    costly    cancer    immune    routinely   

Project "FRAME" data sheet

The following table provides information about the project.

Coordinator
FRAME PHARMACEUTICALS BV 

Organization address
address: Science Park 106
city: AMSTERDAM
postcode: 1098 XG
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAME PHARMACEUTICALS BV NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Frame Cancer Therapeutics is a Dutch start-up that develops effective vaccines against cancer, based on frameshift mutations. Driven by the ambition to provide a therapeutic effect for up to 50% of all cancers, Frame aims to alter the status quo of cancer treatment. Our balanced team consists of top researchers and successful biotech entrepreneurs with a track record including the CEO of Crucell , and founder of ProQR.

The clinical use of so-called checkpoint inhibitors, which activate the immune system, has shown great effects, particularly for treatment of advanced melanoma. Yet, a large group of cancer patients does not benefit from this treatment alone, and the next step is to combine this general activation of the immune system with tumor-specific vaccination. This has just become possible now that entire tumor DNA sequences get to be routinely read within two weeks, as part of clinical care.

The solution that Frame Cancer Therapeutics has developed is a ground-breaking strategy for anti-cancer vaccination using off-the-shelf yet personalized cancer vaccines derived from frameshift mutations. Frame Therapeutics has discovered FRAMES, a source of shared neoantigens induced by frame-shift mutations with unique therapeutic potential. These sequences are usually not expressed in the healthy body, and thus seen as foreign by the immune system. A licensed sets of FRAMES are each specific vaccines for different tumor types (such as breast, lung, kidney, colon, uterine cancer).

Most cancer vaccination strategies are based on point mutations unique for each tumor, requiring costly individualized vaccine manufacturing. Frame Therapeutics is the first company entirely focusing on the development of cancer vaccines based on FRAMES, offering off-the-shelf personalized cancer vaccines. This approach allows for economics of scale, reducing time to treatment from months to days, which is critical to patient health, and which will imprcost/benefit ratio’s.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FRAME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FRAME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

DD-SCAN (2019)

DD-SCAN – AI-based language and multimedia bias checker for corporate communication content

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More